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The energy disruptor metformin 
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Mitochondrial integrity is critical for the regulation of cellular energy and apoptosis. Metformin is an 
energy disruptor targeting complex I of the respiratory chain. We demonstrate that metformin induces 
endoplasmic reticulum (ER) stress, calcium release from the ER and subsequent uptake of calcium into 
the mitochondria, thus leading to mitochondrial swelling. Metformin triggers the disorganization of 
the cristae and inner mitochondrial membrane in several cancer cells and tumors. Mechanistically, 
these alterations were found to be due to calcium entry into the mitochondria, because the swelling 
induced by metformin was reversed by the inhibition of mitochondrial calcium uniporter (MCU). We 
also demonstrated that metformin inhibits the opening of mPTP and induces mitochondrial biogenesis. 
Altogether, the inhibition of mPTP and the increase in mitochondrial biogenesis may account for the 
poor pro-apoptotic effect of metformin in cancer cells.
Maintaining mitochondrial structural integrity is essential for cells to produce energy, overcome environmental 
stresses such as nutrient deprivation and hypoxia and respond to genotoxic agents, including chemotherapy. 
Consequently, the disruption of mitochondrial metabolism sensitizes cells to apoptosis and opens new therapeu-
tic avenues in cancer treatment. Metformin is a biguanide and a widely prescribed anti-diabetic agent, but it is 
also a metabolic disruptor that specifically targets the metabolism of cancer cells1. Several reports have shown that 
this drug inhibits cancer cell growth and has antitumoral effects2, 3. Biguanides inhibit the activity of the mito-
chondrial respiratory chain complex I, thus leading to energetic stress due to the decrease in ATP synthesis4–6. 
Decreased intracellular ATP leads to the activation of the energy sensitive kinase AMP-activated protein kinase 
(AMPK) and the inhibition of mechanistic target of rapamycin (mTORC1), which regulates cell growth and cell 
proliferation and is frequently hyperactivated in tumors. Despite the well-characterized effects of biguanides on 
the respiratory chain, their effects on the mitochondrial ultrastructure are poorly understood.
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Calcium is a central regulator of mitochondrial metabolism; it regulates the activity of several enzymes in the 
tricarboxylic acid cycle and participates in the control of energy metabolism of cells7. Calcium concentration 
is tightly regulated to allow for precise biological processes such as muscle contraction, apoptosis or cell pro-
liferation. The endoplasmic reticulum (ER) is the main intracellular organelle that stores calcium. IP3 (inositol 
1,4,5-trisphosphate) binds to its receptor IP3 receptor (IP3R) and is responsible for the release of calcium from 
the ER. The mitochondria act as cytosolic calcium buffers, and calcium uptake into mitochondrion occurs via an 
electrogenic pathway involving Mitochondrial Calcium Uniporter (MCU)8. The increase in intra-mitochondrial 
calcium concentration induces the opening of mitochondrial permeability transition pore (mPTP), which plays 
an important role in the induction of apoptosis.
To date, knowledge of the action of metformin on mitochondria has been limited to its effect on energy stress, 
which sensitizes cancer cells to apoptosis6. Here, we studied the effects of biguanides on mitochondria. We found 
that metformin and phenformin induced mitochondrial swelling and disorganization of the cristae of the inner 
mitochondrial membrane (IMM) in vitro and in vivo. Metformin induced ER stress and triggered the release 
of calcium from the ER, thus leading to mitochondrial calcium uptake. We also demonstrated that metformin 
inhibited the opening of mPTP. Finally, in response to metformin, mitochondrial biogenesis was induced in can-
cer cells. These findings suggest a novel role for metformin in triggering pro-survival responses in cancer cells.
Results and Discussion
To better characterize the molecular targets of metformin in cancer cells, we performed microarray analysis in 
the prostate cancer cell line LNCaP, which was treated with metformin for 24 h. As expected, we observed an 
increase in the expression of genes encoding energy stress-related proteins such as the Regulated in Development 
and DNA Damage Responses 1 (REDD1) and Sestrin 29, 10 (data not shown). Notably, metformin significantly 
increased the expression of genes implicated in the unfolded protein response (UPR) induced by ER stress, 
such as XBP1, ATF4, ATF6 and DNAJB9 (Fig. 1A). To further characterize and validate the ER stress response 
induced by metformin, we studied the expression of key players of the UPR by western blotting. After only 1 h, 
we observed an increase in the levels of Bip/GRP78 and P-eIF2 followed by an increase in the levels of ATF4 and 
CHOP/DDIT3, a downstream pro-apoptotic factor of the UPR, at 4 h (Fig. 1B and Figure 1-figure supplement 1).
The ER is the major calcium reservoir in cells. Thus, ER stress is often associated with modifications of the 
calcium flux within cells. Therefore, we analyzed the calcium flux in cells treated with metformin by using a 
Fluo-4AM probe. After metformin treatment, we observed a burst of fluorescence corresponding to the release of 
calcium into the cytoplasm (Fig. 1C, Movie S1) even in calcium-free medium that excluded the entry of extracel-
lular calcium (data not shown). To confirm that metformin triggers the release of calcium from the ER, we treated 
the cells with 2-aminoethoxydiphenyl borate (2-APB), an inhibitor and antagonist of IP3R (a calcium releasing 
channel of the ER)11. Treatment with 2-APB hampered the changes in calcium flux induced by metformin, thus 
Figure 1. Metformin induces ER stress and calcium release from the ER. (A) List of genes related to the 
ER stress pathway and significantly upregulated in LNCaP cells treated with 5 mM metformin for 14 h. (B) 
Immunoblotting of LNCaP cells treated with 5 mM metformin for the indicated times by using antibodies 
directed against the indicated proteins implicated in ER stress response. The immunoblot is representative of 
three independent experiments. The blots represent (C) Relative fluorescence intensity of the Fluo-4AM probe, 
measured in LNCaP cells. 2-ABP (40 µM) was added 15 min before the addition of 5 mM metformin at time 0. 
The cellular area was monitored during the experiment (blue line). At least 30 single cells were monitored for 
each condition. The graph represents the mean fluorescence intensity +/− sem. (D) Quantification of IP3R 
mRNA in LNCaP cells treated with metformin for 24 h. p < 0.05 (*); p < 0.01 (**).
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demonstrating that the metformin-induced calcium flux originates in the ER (Fig. 1C). Accordingly, we also 
observed a significant increase in the expression of mRNA encoding for IP3R2 and IP3R3 after metformin treat-
ment (Fig. 1D). The mitochondria display essential calcium buffering properties12; therefore, we hypothesized 
that calcium release from the ER might be buffered by the mitochondria. To determine the effects of metformin 
on the mitochondria, we performed electron microscopy analysis in several cancer cells lines (LNCaP, DU145, 
A375 and A549). We treated the cells with 1 or 5 mM metformin, commonly used concentrations that inhibit 
proliferation by 20% to 60%3, 13, 14. Metformin and phenformin induced swelling of the mitochondria and a pro-
found disorganization of the IMM and cristae without causing visible modifications of the outer mitochondrial 
membrane (OMM) (Fig. 2A and Figure 2-figure supplement 1). Twenty-four hours after metformin withdrawal, 
the size of the mitochondria had partially returned to normal, and the organization of the cristae was similar to 
that of the untreated cells (Figure 2-figure supplement 2). We also demonstrated that the effect on mitochondrial 
swelling occurred as early as 4 h after the addition of metformin (Figure 2-figure supplement 3). Of note, met-
formin did not alter the phenotype of the mitochondria in the normal epithelial prostate cell line P69 (Figure 
2-figure supplement 4). Finally, we did not observe modifications of the mitochondrial ultrastructure in cancer 
cells treated with AICAR, another energy disruptor and activator of AMPK (data not shown).
We then asked whether these modifications occur in vivo. We studied the mitochondria in tumor xenografts 
of LNCaP cells implanted in SCID mice that were given 100 mg/kg of metformin in drinking water for 8 weeks. 
As shown previously13, metformin administration resulted in the expected antitumoral effects (Figure 2-figure 
supplement 5), and the mitochondria were significantly enlarged in the xenografts from the metformin-treated 
mice compared with the mitochondria in the control group (Fig. 2B). Similar results were obtained in TRAMP 
mice that were given 100 mg/kg of metformin for 6 months. In the treated mice, metformin efficiently reduced 
tumor growth and increased the mitochondrial area in the tumor cells (Figure 2-figure supplement 5,6).
Whether the release of calcium is a consequence of ER stress or the inducer remains an open question. 
Thapsigargin and tunicamycin can successfully induced ER stress and then the release of calcium, its accumu-
lation in the mitochondria and finally mitochondrial swelling15. Previous studies have shown that metformin 
induces ER stress in the prostate cancer cell line C4-2B through the induction of miR-708-5p16, but a direct link 
between metformin and mitochondrial calcium homeostasis has never been demonstrated. A direct action of 
metformin on IP3R, which could trigger the release of calcium and consequently ER stress cannot be excluded, 
Figure 2. Metformin induces mitochondrial swelling in cancer cells in vitro and in vivo. (A) Electron 
microscopy (EM) of LNCaP (PCa) and A549 (lung cancer) cells treated with 1 and 5 mM metformin for 
24 h. The graphs represent the mean of the relative mitochondrial area. An example of swollen mitochondria 
with modifications of the IMM is noted with an arrow. The inset shows a magnified view of a representative 
mitochondrion. (B) Electron microscopy images of representative mitochondria from tumor xenografts, and 
quantification of the relative mitochondrial area in the corresponding tumors. The error bars represent the 
standard error of the mean (sem). (C) Electron microscopy images of LNCaP cells treated with metformin 
and 40 µM 2-ABP or 10 µM KB-R7943 for 24 h. Quantification of the mitochondrial area is reported in the 
graph (left panel). For each condition, 60 to 100 mitochondria from several cells were analyzed by EM. (D) 
Quantification of MCU mRNA in LNCaP cells treated with metformin for 24 h. The differences are significant 
with p < 0.05 (*) and p < 0.001 (***).
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but there is no evidence in the literature of such a mechanism of action. The observation that metformin modu-
lates intracellular calcium flux is novel, although a recent study based on transcriptomic and proteomic analyses 
in breast cancer cell lines demonstrated that metformin induced a significant upregulation of pathways involved 
in calcium signaling17.
To validate the direct relationship between the release of calcium from the ER and the swelling of mitochon-
dria, we inhibited IP3R with 2-APB and treated LNCaP cells with metformin. While 2-APB alone did not affect 
the ultrastructure of mitochondria, it significantly blocked the swelling of mitochondria induced by metformin 
(Fig. 2C). To further confirm the implication of calcium, LNCaP cells were treated with two well-characterized 
chemical inhibitors of mitochondrial calcium uniporter (MCU), KB-R794318 and RU-36019. Treatment with the 
inhibitors alone had no effect on the mitochondrial phenotype, whereas in the presence of metformin, KB-R7943 
significantly inhibited mitochondrial swelling (Fig. 2C) and RU-360 preserved the organization of IMM and cris-
tae (Figure 2-figure supplement 7). The transfer of calcium from the ER to the mitochondria involves IP3R (for 
the release from the ER), VDAC1 at the OMM and MCU at the IMM. We found that metformin increased the 
levels of IP3R1, IP3R2 IP3R3 and MCU mRNA as well as VDAC1 protein (Figs 1D, 2D and 4B). Altogether, these 
results demonstrate that there is a direct relationship between the release of calcium and mitochondrial swelling.
The ability of mitochondria to swell in response to different stresses is a biological process that has been known 
for decades20. Hypoxia, through HIF-1α, induces the enlargement of mitochondria, resulting from an atypical 
fusion of mitochondria due to an increase in the expression of mitofusin (Mfn)21. Our previous unpublished data 
showed that metformin did not alter the expression of HIF-1α in LNCaP cells. In addition, we demonstrate here 
that metformin decreased the expression of Mfn2 (Fig. 3A), suggesting that the mechanism implicated in mito-
chondrial swelling upon metformin treatment and hypoxia are different. Interestingly, invalidation of Mfn2 in the 
cerebellum impaired mitochondrial fusion and lead to aberrant mitochondrial ultrastructure and enlargement of 
mitochondria in Purkinje cells22. Other well-known inducers of mitochondrial swelling are perturbator of intra-
cellular K + homeostasis (valinomycin) and more importantly calcium17.
Energy disruptors and activators of AMPK such as rotenone and AICAR lead to the fragmentation of the 
mitochondrial network23. Because metformin is an energy disruptor and activator of AMPK, we studied the 
mitochondrial network by confocal imaging by using the mitochondrial marker Tom20. LNCaP cells have a dis-
connected mitochondrial network under basal conditions, and metformin did not induce the fragmentation of 
Figure 3. Metformin does not induce fission of the mitochondrial network, and mitochondrial swelling is 
partially dependent on AMPK. (A) LNCaP cells were treated with metformin for the indicated times, and Mfn2 
expression was monitored at different time by immunoblotting. (B) LNCaP and DU145 cells were treated for 
24 h with 5 mM metformin and stained with Tom20 for immunofluorescence analysis. Representative IF images 
are shown with the quantification of the morphology of the mitochondrial network. The data from the counting 
of at least 100 cells are shown. (C) LNCaP cells were treated with 5 mM metformin for 24 h in the presence or 
absence of 20 µM of compound C (CC). Representative electronic microscopy images are shown, and the graph 
represents the mean of the relative mitochondrial area. For each condition, 60 to 100 mitochondria from several 
cells were analyzed by EM, p < 0.001 (***).
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the mitochondrial network in DU145 cells (Fig. 3B). However, metformin decreased the expression of mitofusin 
2 (Mfn2), a major regulator of mitochondrial fusion (the opposite process from mitochondrial fission24), thus 
suggesting that although we did not observe a clear fragmentation phenotype induced by metformin, mitochon-
drial fusion may have been altered by metformin. We and others have found that some of the biological effects of 
metformin are not mediated by AMPK9, 25. Therefore, we asked whether AMPK might be involved in the ultras-
tructural modifications induced by metformin. To this end, we treated cells with compound C (CC), a commonly 
used AMPK inhibitor. The inhibitor alone diminished the mitochondrial area and partially, but significantly, 
reversed the swelling and ultrastructural modifications induced by metformin (Fig. 3C). Altogether, our results 
demonstrated that metformin does not induce fragmentation of the mitochondrial network and exerts effects on 
mitochondrial swelling, at least in part, via AMPK.
The relationship between energy stress and modifications of the mitochondrial network has been elucidated 
by the discovery of AMPK function in regulating mitochondrial fragmentation23. In this study, a short-term 
treatment (of minutes) with energy disruptors such as AICAR and rotenone induced fragmentation of the mito-
chondrial network. Metformin is a weak inducer of energy stress, as compared with AICAR and rotenone, thus 
potentially explaining the absence of mitochondrial fragmentation in prostate cancer cells. In addition, our study 
was performed 4 and 24 h after the addition of metformin. AMPK phosphorylated MFF, a receptor for Drp1 
(a major regulator of mitochondrial fission). Interestingly, metformin induced the phosphorylation of MFF in 
hepatocytes23. It would be interesting to determine whether MFF is involved in the swelling of mitochondria.
To further characterize the effects of metformin on mitochondria, we monitored mitochondrial biogene-
sis. Within 24 h, metformin increased the mitochondrial mass, as shown by the augmentation of mitochon-
drial DNA/nuclear DNA ratio and increased signal of MitoTracker Green (Fig. 4A). A direct consequence was 
the increase in the mitochondrial protein NDUFA9 (Complex 1). This effect is driven by an increase in NRF1 
and TFAM, two transcription factors that regulate mitochondrial biogenesis (Fig. 4B). Altogether, these results 
demonstrated that metformin promotes mitochondrial biogenesis in prostate cancer cells. Because mitochondria 
are essential for supplying energy and play a central role in the metabolism of glutamine or synthesis of purines 
and pyrimidines in cancer cells, it would be interesting to investigate the importance of mitochondrial biogenesis 
in the metabolism, survival, and chemotherapy resistance of cancer cells.
Figure 4. Metformin increases mitochondrial biogenesis in cancer cells and inhibits mitochondrial 
permeability transition pore. (A) Mitochondrial DNA content and quantification of MitoTracker Green in 
LNCaP cells treated with metformin for 24 h. The results were obtained from three independent experiments. 
p < 0.05 (*); p < 0.001 (***). (B) Immunoblotting analyses of proteins and transcription factors implicated in 
mitochondrial function, after treatment with 5 mM metformin for 24 and 48 h. (C) Calcium retention capacity 
measured after the incubation of LNCaP cells with 1 µM cyclosporin A for 4 h or 5 mM metformin for 4 h and 
24 h.
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The intra-mitochondrial concentration of calcium determines the opening of mPTP, and metformin has been 
shown to inhibit mPTP in INS-1 (isolated insulinoma cells), HeLa and KB cells and in cardiomyocytes26–28. To 
determine the effect of metformin on mPTP in cancer cells, we studied the Calcium Retention Capacity (CRC) 
of mitochondria in LNCaP and A375 cells treated with metformin. We found that metformin significantly 
increased CRC of mitochondria after 4 h and 24 h in both cell lines (Fig. 4C and Figure 4-figure supplement 1,2). 
Interestingly, the effect of metformin was stronger than that of cyclosporin A, a specific inhibitor of mPTP, and 
co-treatment with cyclosporin A and metformin had similar effects to those of metformin alone in LNCaP 
cells (Fig. 4C). Of note, we observed a significant decrease in the mRNA levels of cyclophilin D (Figure 4-figure 
supplement 3), a putative component of mPTP whose downregulation has been implicated in the retention of 
calcium in mitochondria29. Thus, the inhibition of the opening of mPTP by metformin may explain the weak 
pro-apoptotic potential of metformin.
During apoptosis, the opening of mPTP leads to the release of cytochrome c and allows the entry of ions and 
water into the matrix resulting in mitochondrial swelling30. The closure of mPTP with cyclosporine A, an inhib-
itor of cyclophilin D, reverses this swelling. In contrast with those results, we found that metformin inhibits the 
opening of mPTP and leads to mitochondrial swelling. We suggest that this discrepancy may be due to the mas-
sive influx of calcium into the mitochondria, probably through VDAC1 and MCU, which causes influx of water 
and osmotic swelling independently of mPTP. This hypothesis was supported by the electron microscopy data 
showing a clearer density of the matrix (Figs 2A and 3C and Figure 2-supplement 1 and 2) and by the increase in 
VDAC1 and MCU expression observed in the metformin-treated cells.
One of the novel findings in our study is that metformin modifies mitochondrial homeostasis in a different 
manner from acting directly on the respiratory chain complexes. The accumulation of calcium within the mito-
chondria regulates the intrinsic function of the organelle, including the production of ATP31. Three enzymes of 
the matrix are regulated by calcium: pyruvate dehydrogenase, α-ketoglutarate and isocitrate-dehydrogenase32. 
Activation of these enzymes increases the NADH/NAD ratio and hence the flow of electrons through the res-
piratory chain, thus increasing ATP production. Metformin inhibits complex 1 and decreases ATP production. 
Therefore, we postulate that similarly to the compensatory increase of glycolysis observed in response to met-
formin6, the increase in calcium influx may preserve the energetic status of cancer cells. Likewise, the induction 
of mitochondrial biogenesis may preserve the mitochondrial capacity, thereby increasing the calcium buffering 
abilities of the cells (Fig. 5). Together with the inhibition of mPTP opening, these biological responses protect 
cancer cells against apoptosis. The concept of the protective effect of metformin in normal cells is not new, but 
this effect is not extensively documented in cancer cells. Metformin has been shown to protect primary cortical 
neurons and cardiomyocytes from apoptosis33, 34. It also protects the Isolated insulinoma cell line INS-1β from 
apoptosis induced by high concentrations of glucose, a condition that induces mPTP opening and apoptosis27. 
This protective effect may seem controversial, given the antitumoral effect of the drug. However, we and others 
have shown that metformin is a stronger inhibitor of cell cycle than it is an inducer of apoptosis13, 35, 36.
The relationship between complex 1 and mPTP is complicated. Previous studies have suggested that the inhi-
bition of complex 1 is related to the effect of metformin on mPTP27, 28. It has been proposed that complex 1 inter-
acts with mPTP and modulates its opening through a mechanism similar to the displacement of cyclophilin D by 
cyclosporin A27. However, Batandier et al. have shown that the opening of mPTP directly affects electron transfer 
through complex 137.
In conclusion, we identify a new mechanism of action for metformin involving interference with mito-
chondrial biology through modification of calcium flux. The inhibition of mPTP opening and increase in 
Figure 5. Schematic representation of the effects of metformin on mitochondrial biology in cancer cells. 
The illustrations were created by adopting templates from Servier Medical Arts (http://www.servier.fr/smart/
banque-dimages-powerpoint) which are free for use under the terms of the Creative Commons 3.0 License.
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mitochondrial biogenesis are consistent with the anti-apoptotic and pro-survival response that should be consid-
ered in the future for the potential use of metformin in cancer therapy.
Methods
Cell lines and culture conditions. The cell lines were purchased from ATCC and authenticated by ATCC 
(Manassas, VA, USA). LNCaP cells were cultured in RPMI 1640 medium; DU145, A375 and A549 cells were cul-
tured in DMEM (Invitrogen, Carlsbad, CA, USA) containing 4.5 g/L glucose supplemented with 10% fetal bovine 
serum (FBS) and 100 units/mL penicillin at 37 °C and 5% CO2. The cell line P69 was derived by immortalization of 
human primary prostate epithelial cells with simian virus-40 T antigen38 and grown in RPMI 1640 with 10% FBS.
Chemicals. Metformin and phenformin were suspended in culture medium (without FBS and penicillin) and 
used at the respective concentrations of 5 mM and 100 µM, unless stated otherwise. Metformin, phenformin, 2-APB, 
KB-R7943 and cyclosporin A were purchased from Sigma-Aldrich. RU-360 was purchased from Merck Millipore.
Animal experiments. TRAMP mice were purchased from the Jackson Laboratory (stock # 003135). 
Metformin (100 g/kg/day) was dissolved in drinking water and administered to 6-week-old mice until the day of 
sacrifice at 8 months. For generating the tumor xenografts, LNCaP cells were inoculated subcutaneously (s.c.) with 
BD Matrigel™ matrix (BD Biosciences, Bedford, MA, USA) in five-week-old male SCID mice in both flanks (106 
cells per site). Treatment with metformin in drinking water (100 g/kg/day) was started 3 days after tumor inoculation 
in mice. Tumor size was measured twice weekly for 8 weeks with a caliper, and the tumor volume was calculated 
with the formula π/ 6 × A × B2 (A = larger diameter of the tumor, B = smaller diameter of the tumor) as previously 
described13. The animal experiments were carried out in accordance with French law and were approved by the local 
institutional ethics committee CIEPAL (Comité Institutionnel d’Éthique Pour l’Animal de Laboratoire-Azur).
Electron microscopy. The cells were fixed with 1.6% glutaraldehyde in 0.1 M phosphate buffer at room 
temperature (RT) and then for 16 h at 4 °C. The samples were rinsed with the same buffer, then post-fixed with 1% 
osmium tetroxide and 1% potassium ferrocyanide in 0.1 M cacodylate buffer for 1 h at RT. The cells were rinsed 
with distilled water and embedded in epoxy resin and conventionally processed for thin-sectioning and observed 
with a JEM1400 transmission electron microscope (Jeol, Japan) equipped with a Morada CCD camera (Olympus 
SIS, Germany). The mitochondrial area was calculated by two different investigators in a blinded manner. The 
measurement was performed as follows: for each condition, we delineated the area occupied by individual mito-
chondrion in at least 5 cells (2–3 sections per cells) with ImageJ. This represented 60 to 100 mitochondria per 
condition; the means +/− sem are reported in the graphs.
Calcium Retention Capacity (CRC). Extra-mitochondrial calcium measurement was performed with a 
spectrofluorometer (excitation 500 nm; emission 530 nm) as previously described39. Briefly, cells (equivalent to 
800 µg of proteins) were added to 2 ml of CRC medium (150 mM sucrose, 50 mM KCl, 2 mM KH2PO4, 20 mM 
Tris/HCl and 5 mM Tris succinate). This medium was supplemented with 40 µM digitonin (to permeabilize the 
cells) and Calcium Green-5N (detection probe). The CRC measurements were performed in basal conditions 
or in the presence of the pharmacological compounds 1 µM cyclosporin A or 5 mM metformin. After 2 min of 
incubation, CRC was measured by addition of CaCl2 pulses (40 nmol or 20 nmol calcium) every 2 min until the 
opening of mPTP.
Calcium flux measurements. Real-time calcium measurements were performed in LNCaP cells incubated 
in a physiological Tyrode solution (140 mM NaCl, 4 mM KCl, 1 mM MgCl2, 5 mM HEPES, 1.8 mM CaCl2 and 
11 mM glucose, pH 7.4). The cells were loaded with the Fluo-4AM dye at 37 °C for 15 min and observed with a 
LSM510 Meta microscope (Zeiss). The experiment was independently performed twice, and 32 cells were moni-
tored for each condition and each experiment.
Microarray experiments. Pan-genomic microarrays were printed using the human RNG/MRC oligonucle-
otide collection, as previously described40. The experimental data and associated microarray designs have been 
deposited in the NBCI Gene Expression Omnibus (GEO) under series GSE83673 and platform record GPL 1456. 
Normalizations were performed using the Limma package available from Bioconductor (http://www.biocon-
ductor.org). Intra-slide and inter-slide normalizations were performed using the Print Tip Loess and quantile 
methods, respectively. The means of ratios from all comparisons were calculated, and B-test analysis was per-
formed using the Limma package available from Bioconductor. Differentially expressed genes were selected using 
a Benjamini-Hochberg correction of the p-value for multiple tests on the basis of a p-value below 0.05 and a 
fold-change cutoff (log Ratio > 0.7).
Real-time quantitative PCR. The relative amount of mRNA was determined by quantitative RT-PCR using 
a SYBR Green Master Mix (Applied Biosystems)9. The primer sequences are available upon request.
Western blot analysis. Cell extracts were prepared using lysis buffer1313. Immunoblotting was performed 
with antibodies against SDHA, NDUFA9 (Molecular Probes), NRF1, TFAM, VDAC1 (Santa Cruz Biotechnology) 
and α−tubulin (Sigma-Aldrich). Antibodies against ATF4, GRP78, total and phospho-eIF2α (Ser51) and 
CHOP/DDIT3 were purchased from Cell Signaling Technology. After incubation with the secondary antibod-
ies, the membranes were washed 3 times, incubated with chemiluminescent HRP substrate Immobilon Western 
(Millipore) and scanned with a PXi gel imaging system.
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Statistical analysis. The significance of differences between the means of 2 groups was evaluated using 
Student’s t-tests.
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